Many health AI products contain hidden clinical decisions.
Many founders do not realize this because those decisions are made so early in product development that they stop looking like decisions at all. They start looking like product features.
By the time the product reaches users, those decisions are often invisible, yet they continue influencing the information and guidance the AI provides.
They are product decisions with clinical consequences, and the women using the product are placing trust in those decisions whenever they rely on its health advice.
What a hidden clinical decision looks like
Imagine a FemTech app that uses AI to support women living with fibroids. The app answers questions, explains treatment options, and helps women understand when they should seek medical care.
Long before the first user asks a question, someone has already made a series of important decisions.
“Which clinical guidelines should the AI follow?”
Should it rely on guidance from the World Health Organization, the American College of Obstetricians and Gynecologists, national guidelines from the countries where the product operates, or a combination of several sources?
Those choices influence the clinical information the AI is able to provide. They shape how the product discusses symptoms, treatment options, and when medical attention may be appropriate.
They are among the most important clinical decisions made during product development.
In some early-stage health AI companies, these decisions are made without a structured clinical review process. They may be made by product or engineering teams working with the best information they can find or with limited clinical input, rather than through a documented process that explains why certain evidence was chosen and how those decisions will be reviewed as medical guidance evolves.
That is a hidden clinical decision, and many health AI products have them.
Where they appear
Hidden clinical decisions exist throughout many health AI products.
Evidence sources: Which clinical guidelines, research papers, or medical databases does the AI rely on? Are those sources current? Are they peer-reviewed? Do they reflect the population the product serves?
Knowledge curation: Who decides what information goes into the system and what gets left out? Every inclusion and exclusion influences what users will eventually be told.
Handling conflicting evidence: Clinical guidelines evolve, and studies sometimes reach different conclusions. When evidence conflicts, which source does the product prioritize, and why?
Updating medical information: Clinical recommendations change over time. Does the product have a process for reviewing and updating its clinical knowledge base? Who is responsible for making those updates?
Scope of practice. Where should the AI stop? At what point should it stop answering questions and encourage a user to seek care from a qualified clinician? Defining that boundary is itself a clinical decision.
What this means for founders
The clinical risk in many early-stage health AI products does not come from bad intentions. It comes from capable teams building quickly without recognizing that decisions about health information are also clinical decisions.
A chatbot that tells a woman her symptoms are probably hormonal before suggesting lifestyle changes may influence what she chooses to do next. An AI that recommends a supplement for menstrual symptoms may influence how she manages her condition. These systems may not formally diagnose a patient, but they can still shape health decisions.
If your product provides health information or advice, it almost certainly contains hidden clinical decisions. The real question is whether you know where those decisions are, who made them, and what evidence supports them.
That requires more than having a clinician’s name on an advisory board. It means involving clinical expertise in the decisions that shape what the AI knows, what it says, where it stops, and how it evolves as evidence changes.
The health AI products that stand the test of time are not simply the ones with the most features. They are the ones where hidden clinical decisions become deliberate clinical decisions.
Once those decisions begin influencing patient care, another question inevitably follows:
When one of those decisions contributes to harm, who is actually responsible?
That’s the question we’ll explore in the next article.
Better Woman Health is published weekly.
Subscribe at betterwomanhealth.com to get it directly in your inbox.
Clinical Credibility Toolkit
The Clinical Credibility Toolkit is a free resource designed for FemTech founders building digital tools for women’s health.
It includes the Clinical Credibility Scorecard, a 28-question assessment that helps you identify gaps in your clinical foundation, evidence strategy, safety architecture, and investor readiness, and the Red Flag Detection Checklist, a 25-question assessment that tells you whether your symptom-tracking app can actually detect and act on medical red flags, not just log them.
If you are preparing to pitch, pursuing healthcare partnerships, or simply want to know where your product stands clinically, start here.
Access the toolkit → app.ayomide.me
Thanks for reading. See you soon!
Dr. Ayomide O.
Clinical Strategist & African Market Advisor
Find me on LinkedIn or Book a 1:1 Call
